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Summary
Background Wiskott-Aldrich syndrome is a rare, life-threatening, X-linked primary immunodeficiency characterised 
by microthrombocytopenia, infections, eczema, autoimmunity, and malignant disease. Lentiviral vector-mediated 
haemopoietic stem/progenitor cell (HSPC) gene therapy is a potentially curative treatment that represents an 
alternative to allogeneic HSPC transplantation. Here, we report safety and efficacy data from an interim analysis of 
patients with severe Wiskott-Aldrich syndrome who received lentiviral vector-derived gene therapy.
Methods We did a non-randomised, open-label, phase 1/2 clinical study in paediatric patients with severe Wiskott-
Aldrich syndrome, defined by either WAS gene mutation or absent Wiskott-Aldrich syndrome protein (WASP)
expression or a Zhu clinical score of 3 or higher. We included patients who had no HLA-identical sibling donor 
available or, for children younger than 5 years of age, no suitable 10/10 matched unrelated donor or 6/6 unrelated 
cord blood donor. After treatment with rituximab and a reduced-intensity conditioning regimen of busulfan and 
fludarabine, patients received one intravenous infusion of autologous CD34+ cells genetically modified with a 
lentiviral vector encoding for human WAS cDNA. The primary safety endpoints were safety of the conditioning 
regimen and safety of lentiviral gene transfer into HSPCs. The primary efficacy endpoints were overall survival, 
sustained engraftment of genetically corrected HSPCs, expression of vector-derived WASP, improved T-cell function, 
antigen-specific responses to vaccinations, and improved platelet count and mean platelet volume normalisation. 
This interim analysis was done when the first six patients treated had completed at least 3 years of follow-up. The 
planned analyses are presented for the intention-to-treat population. This trial is registered with ClinicalTrials.gov 
(number NCT01515462) and EudraCT (number 2009-017346-32).
Findings Between April 20, 2010, and Feb 26, 2015, nine patients (all male) were enrolled of whom one was excluded 
after screening; the age range of the eight treated children was 1·1–12·4 years. At the time of the interim analysis 
(data cutoff April 29, 2016), median follow-up was 3∙6 years (range 0∙5–5∙6). Overall survival was 100%. Engraftment 
of genetically corrected HSPCs was successful and sustained in all patients. The fraction of WASP-positive 
lymphocytes increased from a median of 3∙9% (range 1·8–35·6) before gene therapy to 66∙7% (55·7–98·6) at 
12 months after gene therapy, whereas WASP-positive platelets increased from 19∙1% (range 4·1–31·0) to 76∙6% 
(53·1–98·4). Improvement of immune function was shown by normalisation of in-vitro T-cell function and 
successful discontinuation of immunoglobulin supplementation in seven patients with follow-up longer than 1 year, 
followed by positive antigen-specific response to vaccination. Severe infections fell from 2∙38 (95% CI 1·44–3·72) 
per patient-year of observation (PYO) in the year before gene therapy to 0∙31 (0·04–1·11) per PYO in the second year 
after gene therapy and 0∙17 (0·00–0·93) per PYO in the third year after gene therapy. Before gene therapy, platelet 
counts were lower than 20 × 10⁹ per L in seven of eight patients. At the last follow-up visit, the platelet count had 
increased to 20–50 × 10⁹ per L in one patient, 50–100 × 10⁹ per L in five patients, and more than 100 × 10⁹ per L in 
two patients, which resulted in independence from platelet transfusions and absence of severe bleeding events. 
27 serious adverse events in six patients occurred after gene therapy, 23 (85%) of which were infectious (pyrexia 
[five events in three patients], device-related infections, including one case of sepsis [ four events in three patients], 
and gastroenteritis, including one case due to rotavirus [three events in two patients]); these occurred mainly in the 
first 6 months of follow-up. No adverse reactions to the investigational drug product and no abnormal clonal 
proliferation or leukaemia were reported after gene therapy.
Interpretation Data from this study show that gene therapy provides a valuable treatment option for patients with 
severe Wiskott-Aldrich syndrome, particularly for those who do not have a suitable HSPC donor available.
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Introduction
Wiskott-Aldrich syndrome is a rare, X-linked, primary 
immunodeficiency characterised by microthrombo cyto-
penia, recurrent infections, eczema, and increased risk for 
autoimmunity and lymphoid malignant diseases.1,2 The 
disease is due to mutations in the WAS gene, which 
encodes the Wiskott-Aldrich syndrome protein (referred 
to as WASP)—an intracellular key regulator of actin 
polymerisation.2,3 WASP-deficient immune cells have 
compromised immunological synapsis formation, cell 
migration, and cytotoxicity.1 Survival of patients with 
Wiskott-Aldrich syndrome is dependent on the severity of 
the disease. Patients with classic severe phenotype (Zhu 
clinical score ≥3) have an approximate survival of 15 years 
with supportive treatment only.4,5
Haemopoietic stem/progenitor cell (HSPC) trans-
plantation from an HLA-identical sibling donor is the 
treatment of choice for patients with Wiskott-Aldrich 
syndrome, but such a donor is not always available.6–10 
HSPC transplantation from an HLA-matched unrelated 
donor can also be curative but can be hampered by 
development of graft-versus-host disease, graft rejection, 
or autoimmune complications if complete chimerism is 
not achieved.8 The best outcome for unrelated HSPC 
transplantation occurs when the recipient is younger 
than 5 years of age at the time of transplant.9,10
An alternative potentially curative option for patients 
with Wiskott-Aldrich syndrome is gene therapy, consisting 
of a reduced intensity conditioning regimen followed by 
infusion of ex-vivo genetically corrected autologous 
HSPCs. Ex-vivo gene therapy has several potential 
advantages, including absence of graft-versus-host disease 
and decreased toxicity due to the reduced intensity 
conditioning regimen. In a previous trial using a γ-retro-
viral vector under the control of a strong viral promoter, 
gene therapy was feasible and resulted in functional 
Research in context
Evidence before this study
We searched PubMed from database inception to Nov 25, 2018, 
for relevant studies of treatments for Wiskott-Aldrich 
syndrome, including acronyms, synonyms, and closely related 
words for the terms “Wiskott-Aldrich syndrome”, “gene 
therapy”, and “haematopoietic stem cell transplantation”. 
We did not restrict our search by study design or language. 
We identified further studies by searching relevant websites and 
the reference lists of reports identified by our search. The only 
curative treatment for Wiskott-Aldrich syndrome is allogeneic 
haemopoietic stem/progenitor cell (HSPC) transplantation with 
a suitable HLA-matched donor. However, many patients do not 
have such a donor available, and treatment can be hampered by 
development of graft-versus-host disease, graft rejection, 
and autoimmune complications if complete chimerism is not 
achieved. Proof-of-principle for an autologous approach with 
gene therapy came from a previous trial using a γ-retroviral 
vector carrying a functional WAS gene under the control of a 
strong viral promoter. However, integration-driven 
overexpression of proto-oncogenes triggered development of 
severe side-effects such as leukaemia and myelodysplasia in 
most patients. To address the safety issues with γ-retroviral 
vectors for Wiskott-Aldrich syndrome, a self-inactivating 
lentiviral vector was developed, encoding for human 
Wiskott-Aldrich syndrome protein (WASP) under the control of 
a 1∙6 kb reconstituted WAS gene promoter. In this construct the 
transgene is expressed in the context of the proper endogenous 
regulatory elements, rather than a viral promoter. A phase 1/2 
clinical study on this lentiviral vector-derived gene therapy 
combined with a reduced-intensity conditioning regimen was 
initiated in patients with Wiskott-Aldrich syndrome in 2010, 
and preliminary results for the first three patients treated 
(follow-up of 20–32 months) were reported in 2013. An 
additional study, using the same lentiviral vector construct but 
manufactured by a different process reported treatment of 
seven patients with Wiskott-Aldrich syndrome, with follow-up 
of 7–42 months.
Added value of this study
We report findings of an interim analysis of the phase 1/2 
clinical study that was initiated in 2010. Eight patients with 
Wiskott-Aldrich syndrome are included in the analysis of safety 
and efficacy data, with median follow-up of 3∙6 years (range 
0∙5–5∙6), the longest follow-up published to date. After a 
reduced-intensity conditioning regimen and subsequent 
infusion of transduced CD34+ cells, all eight patients showed 
good haematological reconstitution and sustained 
engraftment of transduced cells. WASP expression was 
increased in peripheral blood myeloid and lymphoid lineages 
and in platelets. Significant improvement of immune function 
was seen by normalisation of in-vitro T-cell function, 
pronounced reduction of severe infections, and successful 
discontinuation of immunoglobulin supplementation followed 
by response to vaccination. Platelet counts increased 
substantially, resulting in platelet transfusion independence 
and absence of severe bleeding events.  
Implications of all the available evidence
Lentiviral vector-mediated HSPC gene therapy is an 
alternative, potentially curative, treatment for patients with 
Wiskott-Aldrich syndrome that could be administered to a 
wider range of patients than allogeneic HSPC transplantation 
and might result in fewer complications. This possibility will 
be confirmed by longer follow-up of patients treated with 
gene therapy.
Articles
www.thelancet.com/haematology   Vol 6   May 2019 e241
correction of blood cell defects.11 However, insertions of 
the γ-retroviral vector were clustered in proto-oncogenes; 
integration-driven overexpression of these genes triggered 
the development of severe side-effects such as leukaemia 
and myelodysplasia in most patients.11
To address the safety issues with γ-retroviral vectors 
for Wiskott-Aldrich syndrome, we developed a self-
inactivating lentiviral vector encoding human WASP 
under the control of a 1∙6 kb reconstituted WAS gene 
promoter.12 The use of this endogenous promoter ensures 
that the transgene is expressed in the context of the proper 
endogenous regulatory elements.3 Its moderate enhancer 
activity combined with the self-inactivating long-terminal 
repeat design and absence of preference to integrate in or 
near oncogenes reduces the risk of insertional muta-
genesis, as shown by in-vitro transformation assays13 and 
preclinical in-vivo studies in WASP-deficient mice.14,15
In a phase 1/2 clinical study, autologous CD34+ cells 
genetically modified with a lentiviral vector encoding 
for human WAS cDNA12,14 were re-infused to patients 
with severe Wiskott-Aldrich syndrome after a reduced-
intensity conditioning regimen.16 Preliminary data from 
the initial follow-up (20–32 months) of the first 
three patients in the study have been reported.16 Here, 
we report data from an interim analysis that was planned 
in the study protocol to be done after the first six patients 
treated had completed at least 3 years of follow-up. 
This interim analysis was agreed with the European 
Medicines Agency (EMA) and its paediatric committee 
(PDCO) as adequate to support a marketing authorisation 
appli cation. Further analyses are planned when all 
patients in the study have completed 3 years of follow-up 
and again when all patients have completed at least 
8 years of follow-up.
Methods
Study design and participants
We undertook an open-label, non-randomised, phase 1/2 
clinical study at the Pediatric Clinical Research Unit and 
Pediatric Immunohematology and Bone Marrow Trans-
plantation Unit of the San Raffaele Scientific Institute 
(Milan, Italy). The drug product (autologous CD34+ cells 
genetically modified with a lentiviral vector encoding for 
human WAS cDNA), trial design, and procedures have 
been described previously (appendix pp 1–3).16 Patients 
were eligible for the study if they had Wiskott-Aldrich 
syndrome defined by a WAS genetic mutation, with absent 
WASP expression, severe WAS mutation,2 or severe 
clinical phenotype (Zhu clinical score ≥3).3 We included 
patients if they had no HLA-identical sibling donor or, for 
children younger than 5 years of age, no suitable 10/10 
matched unrelated donor or 6/6 unrelated cord blood 
donor.9 We excluded patients who either had HIV infection, 
neoplasia, cytogenetic alterations typical of myelodisplastic 
syndrome or acute myeloid leukaemia, or end-organ 
functions or any other severe disease which, in the judg-
ment of the investigator, would have been inap propriate 
for entry into this study. We also excluded patients who 
had undergone an allogeneic HSPC transplant in the 
previous 6 months or earlier and had evidence of residual 
cells of donor origin. The conditions required by the study 
protocol for enrolment of patients have been assessed and 
fulfil ment of the inclusion and exclusion criteria 
have been assessed in the screening phase, during which 
time eligible patients underwent clinical, laboratory, and 
instrumental pre treat ment work-up, including additional 
disease-specific assess ments. We obtained a bone marrow 
aspirate to assess morphology, cellularity, CD34+ cell 
content, and clonogenic activity.
The protocol and other trial-related materials were 
approved by the independent ethics committee of the 
San Raffaele Scientific Institute and the Italian regulatory 
authority (Agenzia Italiana del Farmaco [AIFA]). Written 
informed consent was provided by parents or legal 
representatives of patients before initiation of study-
specific procedures.
For the assessment of WASP expression and 
T lymphocyte proliferative responses, we obtained peri-
pheral blood samples from healthy controls, in accordance 
with the Declaration of Helsinki. Informed consent was 
approved by the institutional ethics committee of the San 
Raffaele Hospital in 2009 (Tiget Periblood protocol).
Procedures
We obtained a backup of autologous HSPCs and cryo-
preserved them approximately 5–10 weeks before the 
planned day of gene therapy, either by bone marrow 
harvest or by leukapheresis, after administration of 
granulocyte colony-stimulating factor (in most cases, 
lenograstim), with or without plerixafor. If the HSPC 
source was mobilised peripheral blood, we also gathered 
cells for future transduction at this time and cells were 
cryopreserved until the start of gene transduction on 
day –3. If the HSPC source was bone marrow, we 
obtained cells from iliac crests under general anaesthesia 
on day –3.
We administered intravenous CD20 monoclonal 
antibody (rituximab 375 mg/m²) on day –22. The 
reduced-intensity conditioning regimen comprised 
eight doses of intravenous busulfan administered every 
6 h from days –3 to –1 (plus an optional ninth dose to 
reach the target cumulative busulfan area under the 
curve [AUC], if needed) and two doses of intravenous 
fludarabine (30 mg/m² per day) on days –3 and –2. 
We monitored busulfan pharmacokinetics and adjusted 
the dose to avoid excessive toxicity or insufficient 
exposure.17 Initially, the target busulfan AUC range 
was 4500–6000 ng × h / mL per dose, equivalent to a 
cumulative target of 36 000–48 000 ng × h / mL. 
We amended the cumulative busulfan AUC target to 
48 000 (±10%) ng × h / mL after treatment of six patients. 
The actual doses and AUC of busulfan received by each 
patient are summarised in the appendix (p 13). One 
intravenous infusion of autologous CD34+ cells 
See Online for appendix
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obtained from bone marrow harvest or mobilised 
peripheral blood stem cells and transduced with the 
WAS lentiviral vector12,14 was given on day 1. The 
planned target dose was 5–10 × 10⁶ CD34+ cells per kg, 
with an acceptable range of 2–20 × 10⁶ cells per kg. 
CD34+ cell manipulation and transduction procedures 
were done at MolMed SpA (Milan, Italy), as described 
previously.16 Patients were in hospital for a median 
of 52 days (range 36–82), during which time they 
underwent chemotherapy, gene therapy, and short-term 
follow-up, then they were followed up as outpatients 
unless invasive procedures were needed or complications 
arose. Clinical examinations were scheduled during 
screening, at baseline (timing of baseline varied by 
patient and was from the end of screening to the day 
before harvest of peripheral blood cells or the day before 
rituximab administration [which was on day –22]), 
day –14, day 1 (when gene therapy was initiated), day 7, 
day 14, day 21, day 30, day 60, day 90, day 180, and year 1, 
year 1∙5, year 2, year 2∙5, year 3, and annually to year 8. 
After treatment, patients’ assessment also included 
routine laboratory tests, microbiological tests, diagnostic 
imaging, immune profiling, and specific immunological 
tests, according to the time schedule defined in the study 
protocol. All adverse events—regardless of seriousness 
or relation to the drug product—have been recorded in 
trial case report forms, and the investigators have kept 
detailed records of all reported adverse events. We used 
Common Terminology Criteria for Adverse Events for 
grading of adverse events, or clinical judgment if this 
grading was not applicable.
We assessed quality of life with a questionnaire 
(appendix pp 1, 2) given to patients’ parents, which was 
composed of questions about lifestyle and life in a 
protected environment (eg, hygiene restrictions, food, 
contact with other children), attendance at school 
(according to age), social ability with peers, and practice 
of sport activities (according to age). The questionnaire 
was given to parents before treatment and then every 
year at the follow-up visit (starting in year 1 after gene 
therapy). 
Outcomes
The primary study objectives were to assess the safety of 
drug product administration after a reduced-intensity 
conditioning regimen, the long-term engraftment of 
WASP-expressing gene-transduced cells, and the efficacy 
of gene therapy in terms of improvement in immune 
function and thrombocytopenia. Secondary study 
objectives were to assess the efficacy of gene therapy in 
improving the patient’s clinical condition with respect to 
severe infections, bleeding episodes, auto immunity 
measures, and eczema.
Details of safety and efficacy endpoints are in the 
appendix (p 1). The primary safety endpoints were safety 
of the conditioning regimen and short-term and long-
term safety of lentiviral gene transfer into HSPCs. 
The primary efficacy endpoints were overall survival, 
sustained engraftment of genetically corrected HSPCs, 
expression of vector-derived WASP, improved T-cell 
function, antigen-specific responses to vacci nations, and 
improved platelet count and mean platelet volume 
normalisation. The endpoints for this study are the same 
as those defined after initial follow-up of the first three 
patients treated, reported previously.16
Statistical analysis
The sample size was calculated based on the low 
prevalence of Wiskott-Aldrich syndrome and the degree 
of novelty of the proposed experimental approach. Thus, 
we planned to treat eight patients over an estimated 
5-year recruitment period. Planned analyses are 
presented for the intention-to-treat population, defined 
as all patients treated with lentiviral gene therapy in the 
study, and consider data available within the clinical 
database. Data are summarised using descriptive 
statistics. Adverse events, serious adverse events, infec-
tions, bleeding events, number of platelet transfusions, 
days in hospital, and anti-infective treatments are 
summarised as rates (number of events or treatments 
per patient-year of observation [PYO]). We calculated 
95% CIs for crude rates based on the Poisson exact 
method. We used Medidata Rave 2017.2.3 software to 
collect data in this study (via electronic case report 
forms). For analysis of descriptive statistics we used SAS 
version 9.4, and for data analysis and graphical 
representation of data we used Microsoft Excel 365 and 
Graph Pad Prism version 5 for Mac OS X.
This trial is registered with ClinicalTrials.gov (number 
NCT01515462) and EudraCT (number 2009-017346-32).
Role of the funding source
The funder had no role in study design but did contribute 
to protocol amendments. The funder had a role in data 
collection, data analysis, data interpretation, and writing 
of the report. The corresponding author had full access 
to all data in the study and had final responsibility for the 
decision to submit for publication.
Results
The clinical protocol was approved by the Italian regulatory 
authority (AIFA) on March 15, 2010. Between 
April 20, 2010, and Feb 26, 2015, nine patients (all male) 
were enrolled to the study, of whom eight received gene 
therapy. The fifth patient enrolled was withdrawn during 
screening because he had a revertant mutation in more 
than 5% of lymphoid cells, which was an exclusion 
criterion at that time (figure 1). The protocol was 
subsequently amended in April, 2014, to allow treatment 
of subsequent patients with revertant mutations (approved 
by the San Raffaele Scientific Institute ethics committee 
on April 14, 2014, and by AIFA on April 17, 2014).
At the time of this planned interim analysis (data cutoff 
April 29, 2016), median follow-up was 3∙6 years (range 
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0∙5–5∙6). Six patients had at least 3 years of follow-up; of 
the other two patients, one had 1·5 years of follow-up and 
the other had 6 months of follow-up (appendix p 14). All 
eight patients were alive and well at the time of this 
interim analysis.
The median age of patients on the day of gene therapy 
was 2∙2 years (range 1∙1–12∙4). Baseline characteristics 
for each patient are summarised in table 1. The observed 
WAS gene mutations were nonsense, deletions, missense, 
and a novel complete inversion of exons 1–7 that included 
part of the promoter region.18 All eight patients had severe 
clinical disease before gene therapy (Zhu clinical score 
range 3–5A). Before gene therapy, five patients had 
less than 5% of peripheral blood lymphocytes expressing 
WASP and three patients had residual WASP expression 
(20–36% of peripheral blood lympho cytes). All patients 
(n=8) had recurrent infections, eczema, thrombo-
cytopenia, bleeding, and immune disorders (eg, allergies 
and autoimmune or auto inflammatory manifestations; 
table 1).
The CD34+ cell source was bone marrow for five patients, 
mobilised peripheral blood for two patients, and a 
combination of both for one patient. Mobilised peripheral 
blood stem cells were obtained after administration of 
either lenograstim (n=2) or lenograstim and plerixafor 
(n=1). The dose of drug product administered was 
7·0–16∙8 × 10⁶ CD34+ cells per kg. CD34+ cells sourced 
from bone marrow had a transduction efficiency of 
91–100%, with an average vector copy number per genome 
of 1∙9–4∙3. CD34+ cells sourced from peripheral blood 
had a trans duction efficiency of 88–96% with an average 
vector copy number per genome of 1∙4–3∙2 (table 1).
The reduced-intensity conditioning regimen was not 
associated with any unexpected toxic effects during the 
first 100 days after gene therapy. All eight patients had 
severe neutropenia, with an absolute neutrophil count of 
0∙2 × 10⁹ cells per L or lower (appendix p 13). All eight 
patients had adverse events during follow-up but none of 
the events was judged by the investigator to be related to 
the drug product. No patient had severe mucositis.
Engraftment was successful in all eight patients 
(absolute neutrophil count ≥0∙5 × 10⁹ cells per L within 
60 days; appendix pp 4, 13) without the need for backup 
autologous cell administration. Time to neutrophil 
engraftment ranged from 18 days to 59 days. One patient 
(patient 4) needed administration of granulocyte colony-
stimulating factor (on day 42 and day 44) for delayed 
neutrophil recovery.
The incidence of adverse events and serious adverse 
events was highest in the first 6 months of follow-up then 
declined and reached a plateau from 6 months after gene 
therapy onwards (table 2). The rate of serious adverse 
events per PYO declined from 4·8 (95% CI 2·9–7·4) 
during the first 6 months of follow-up after gene therapy 
to 0·6 (0·2–1·6) between 1 year and 2 years of follow-up 
and to 0·2 (0·0–0·9) between 2 years and 3 years of 
follow-up. Likewise, the rate of adverse events per PYO 
declined from 65·5 (95% CI 57·8–73·9) during the first 
6 months of follow-up after gene therapy to 22·1 
(17·5–27·6) between 6 months and 12 months of follow-
up and to 15·8 (12·8–19·3) between 2 years and 3 years of 
follow-up. No adverse event or serious adverse event was 
considered to be related to drug product by the 
investigator. Rates of adverse events commonly associated 
with Wiskott-Aldrich syndrome (eg, bleeding events, 
eczema, and infections) declined after gene therapy. 
27 serious adverse events in six patients were reported 
after gene therapy, of which 23 (85%) were of infectious 
origin, including pyrexia (five events in three patients), 
device-related infections including one case of sepsis 
(four events in three patients), and gastroenteritis of 
which one case was due to rotavirus (three events in two 
patients; table 2).
Transient decreases in haematological indices were 
noted after the conditioning phase in all eight patients. 
Results of serum chemistry tests did not show any 
consistent patterns of clinical concern (data not shown).
No adverse reactions to the drug product were reported 
within 48 h of infusion. No adverse findings were reported 
from replication competent lentivirus assessments and no 
evidence was seen of abnormal clonal proliferation or 
leukaemia development after gene therapy. No antibody 
against WASP was detected in any patient after gene 
therapy.
Data for the first six patients with at least 3 years of 
follow-up were analysed, and 184 745 unique insertion 
sites were identified from bone marrow CD34+ cells, 
bone marrow precursors, and peripheral blood mature 
cells from lymphoid and myeloid lineages at different 
timepoints after gene therapy. The diversity of the clonal 
Figure 1: Study design
PBSC=peripheral blood stem cell.
9 patients were enrolled after parents provided informed consent
9 patients underwent preliminary screening for inclusion criteria
8 patients had baseline clinical, laboratory and instrumental 
 assessments, and back-up collection and storage
8 patients underwent PBSC mobilisation or bone marrow harvest, 
 received chemotherapy and gene therapy schedule
7 patients were followed up for safety and efficacy from day 1 for 
 longer than 1 year
6 patients were followed up for safety and efficacy from day 1 for 
 longer than 3 years
8 patients included in the study
1 patient excluded (did not meet inclusion criteria) 
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repertoire of engineered cells was maintained at a high 
complexity level starting from around 1 year after gene 
therapy without major inbalances up to and including the 
latest follow-up analysed (appendix p 5). The common 
insertion sites detected in all six patients reflect the classic 
insertional pattern of lentiviral vectors, including PACS1 
and KDM2A previously reported in metachromatic 
leukodystrophy,19 adrenoleukodystrophy, and β thal-
assemia20 gene therapy trials and not associated with 
clonal expansion. No enrichment for genomic areas 
associated with insertional mutagenesis events was 
detected when comparing data at 12–18 months and 
30–36 months after gene therapy (appendix p 6).
All seven patients who were followed up for at least 
1 year after gene therapy (figure 1) had adequate 
engraftment of genetically corrected colony-forming cells 
in bone marrow (figure 2A). Engraftment was sustained 
over time in both bone marrow and peripheral blood cell 
lineages (figures 2B, 2C). Gene-corrected granulocytes 
(CD15+), megakaryocytic precursors (CD61+), erythroid 
cells (glycophorin A-positive [GlyA+]), B cells (CD19+), 
and natural killer (NK) cells (CD56+) were detectable 
from 1 month after gene therapy. T-cell engraftment 
was slower compared with other lineages, as expected 
by the required time for T-cell development through 
the thymus, with transduced T cells appearing from 
3 months after gene therapy. Transduced cell engraftment 
was higher in lymphoid lineages (CD3+, CD4+, CD8+, 
CD19+, and CD56+) compared with myeloid lineages 
(CD15+, CD61+, and GlyA+) because of their known 
selective advantage.
Lymphocyte counts decreased after conditioning, as 
expected, then increased progressively. At the latest 
follow-up visit, T-cell counts (both CD4+ helper and 
CD8+ cytotoxic T lymphocytes), B-cell counts, and 
NK cell counts were normal for age in all eight 
patients,21 apart from one patient’s (patient 7) total and 
CD8+ T-cell counts, which were just below the normal 
range (appendix pp 15–20). Naive CD4+ T cells were 
normal in four of eight patients at the last follow-up 
visit, similar to pretreatment levels (appendix p 21).22 
The fraction of lymphocytes expressing WASP was 
substantially improved in all eight patients, with a 
ten times increase in the median value compared with 
baseline seen at 3 months after gene therapy (range 
11–72%) and a 20 times increase recorded consistently 
0–6 months after 
gene therapy (n=8)
6–12 months after 
gene therapy (n=8)
1–2 years after gene 
therapy (n=7)
2–3 years after gene 
therapy (n=6)
≥3 years after gene 
therapy (n=5)*
Total after gene therapy 
(n=8) 
Patients Events Patients Events Patients Events Patients Events Patients Events Patients Events 
Any serious adverse event 6 19 1 1 3 4 1 1 1 2 6 27
Infection-related event
Pyrexia 2 2 1 1 1 2 0 0 0 0 3 5
Device-related infection 2 2 0 0 1 1 0 0 0 0 2 3
Acute respiratory distress 
syndrome†
1 1 0 0 0 0 0 0 0 0 1 1
Aspergillus infection 1 1 0 0 0 0 0 0 0 0 1 1
Bacterial sepsis† 1 1 0 0 0 0 0 0 0 0 1 1
Device-related sepsis 1 1 0 0 0 0 0 0 0 0 1 1
Disseminated 
intravascular coagulation†
1 1 0 0 0 0 0 0 0 0 1 1
Influenza 1 1 0 0 0 0 0 0 0 0 1 1
Interstitial lung disease 1 1 0 0 0 0 0 0 0 0 1 1
Gastroenteritis 1 2 0 0 0 0 0 0 0 0 1 2
Pneumonia aspiration 1 1 0 0 0 0 0 0 0 0 1 1
Viral infection 1 1 0 0 0 0 0 0 0 0 1 1
Gastroenteritis rotavirus 0 0 0 0 1 1 0 0 0 0 1 1
Tooth abscess 0 0 0 0 0 0 1 1 0 0 1 1
Cellulitis 0 0 0 0 0 0 0 0 1 1 1 1
Pneumonia bacterial 0 0 0 0 0 0 0 0 1 1 1 1
Other type of event
Electrolyte imbalance 1 1 0 0 0 0 0 0 0 0 1 1
Food allergy 1 1 0 0 0 0 0 0 0 0 1 1
Irritability 1 1 0 0 0 0 0 0 0 0 1 1
Neutropenia 1 1 0 0 0 0 0 0 0 0 1 1
MedDRA (version 19.0) preferred terms are used. MedDRA=Medical Dictionary for Regulatory Activities. *Range 3∙0–5∙6 years. †These three events were linked, occurring in patient 2, and were considered to be 
part of the same condition.
Table 2: Serious adverse events after gene therapy
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at 12 months after gene therapy (figure 3A). The fraction 
of WASP-positive lymphocytes increased from a 
median of 3∙9% (range 1·8–35·6) before gene therapy 
to 66∙7% (55·7–98·6) at 12 months after gene therapy. 
A selective advantage was noted in lymphoid lineages, 
particularly T cells, which showed a higher level 
of expression compared with myeloid lineages 
(appendix pp 7, 8). The T-cell proliferative response to 
anti-immobilised CD3 (anti-CD3i) was severely 
compromised in all eight patients before gene therapy 
and steadily improved after gene therapy. In the 
six patients with 3 years of follow-up, the proliferative 
response at 3 years was comparable with the response 
in T cells from healthy controls (figure 3B). The 
proliferative response to phytohaemagglutinin was 
normal in seven of the eight patients and returned to 
normal levels in all seven patients with follow-up at 
least 1 year after gene therapy, including the patient 
with abnormal levels before gene therapy.
The improvement in immune function was accom-
panied by clinical benefit. The rate of severe infections 
increased in the first 6 months after gene therapy, in 
accordance with the effects of the conditioning regimen, 
but declined strikingly thereafter to approximately an 
order of magnitude lower than the rate in the year 
before treatment (figure 3C). Severe infections fell from 
2∙38 (95% CI 1·44–3·72) events per PYO in the year 
before gene therapy to 0∙31 (0·04–1·11) events per PYO 
in the second year after gene therapy and 
0∙17 (0·00–0·93) events per PYO in the third year after 
gene therapy. No reactivation of cytomegalovirus was 
detected after 6 months of follow-up in three patients 
who had chronic cytomegalovirus infection before 
treatment. The rate of anti-infective drug use 2–3 years 
after gene therapy was approximately four times lower 
than the rate in the year before treatment 
(11∙3 treatments per PYO vs 42∙0 treatments per PYO). 
The number of days spent in hospital also declined 
substantially from 6 months after gene therapy onwards 
(figure 3D). Eczema scores improved in all six patients 
who reached at least 3 years of follow-up, and eczema 
had completely resolved in five patients by 3 years 
(figure 3E).
At the time of this interim analysis, intravenous 
immunoglobulin had been discontinued in seven patients 
with follow-up longer than 1 year (median time to dis-
continuation after gene therapy, 1·7 years [IQR 0∙9–3∙0]). 
Serum immunoglobulin levels before and after gene 
therapy are reported in the appendix (p 22). Immuno-
logical status was considered to be sufficiently improved 
to allow the start of childhood vaccinations in five patients. 
A protective antibody response was shown in all 
five patients to tetanus toxoid, diphtheria, Haemophilus 
influenzae type B, and hepatitis B. Four of five patients 
also had a protective response to Bordetella pertussis. 
Protective levels of IgG antibodies against Streptococcus 
pneumoniae were detected in one of five assessable 
patients after polysaccharide pneumococcal vaccine and 
in three of four assessable patients after pneumococcal 
conjugated vaccine (appendix pp 23, 24).
Figure 2: Multilineage engraftment of genetically corrected haemopoietic stem cells and peripheral blood 
cells in eight patients with Wiskott-Aldrich syndrome treated with lentiviral vector gene therapy
 (A) In-vivo engraftment of transduced progenitor cells in bone marrow (LV-positive colonies). (B) Median VCN per 
cell in bone marrow cell lineages. (C) Median VCN per cell in peripheral blood cell lineages. No vector was detected 
in bone marrow total cells analysed before gene therapy. LV=lentiviral vector. VCN=vector copy number. 
GlyA=glycophorin A. NK=natural killer.
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The proportion of platelets expressing WASP, as 
measured by flow cytometry, progressively improved over 
time in all eight patients after gene therapy (figure 4A; 
appendix pp 9, 10). WASP-positive platelets increased 
from 19∙1% (range 4·1–31·0) before gene therapy to 
76∙6% (53·1–98·4) at 12 months after gene therapy. The 
ratio of mean fluorescence intensity in platelets of patients 
normalised to those of healthy controls increased from a 
median of 0·18 (0·01–0·31) before gene therapy to 0·43 
(0·20–1·03) at 1 year after gene therapy. A substantial 
improvement in platelet count was also seen (figure 4B). 
Before gene therapy, platelet counts were lower than 
20 × 10⁹ per L in seven of eight patients. At the last follow-
up visit, the platelet count had increased to 20–50 × 10⁹ per L 
in one patient, 50–100 × 10⁹ per L in five patients, and 
more than 100 × 10⁹ per L in two patients, which resulted 
in independence from platelet transfusions and absence 
of severe bleeding events, although platelets counts 
remained below the lower limit of the normal range 
in most patients. Mean platelet volume, which is 
Figure 3: Immune reconstitution and clinical benefit
Gene therapy was administered on day 1 (month 0). (A) Percentage of peripheral blood lymphocytes expressing WASP, as measured by flow cytometry. (B) T-cell proliferation response (expressed as SI) 
after incubation with increasing concentrations of anti-CD3i antigen, by observation period. Boxes represent upper and lower quartiles (outliers excluded). Horizontal line within the box is the median. 
Whiskers represent most extreme points ≤1∙5 × IQR. Control data are from 12 healthy children. (C) Rate of severe infections (events per PYO) for each observation period. Error bars represent the 
95% CI. (D) Number of days in hospital (days per PYO) for each observation period. Error bars represent the 95% CI. (E) Eczema scores are 1 (absent), 2 (mild), 3 (moderate), and 4 (severe). Six patients 
were followed up for at least 3 years after gene therapy. WASP=Wiskott-Aldrich syndrome protein. SI=stimulation index. Anti-CD3i=anti-immobilised CD3. PYO=patient-year of observation.
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characteristically reduced in patients with Wiskott-Aldrich 
syndrome, was within the normal range (7∙4–10∙9 fL) in 
seven assessable patients at 1 year after gene therapy and 
remained at this level except for a transient dip for one 
patient (patient 6) at year 2. All eight patients needed 
platelet transfusions before gene therapy (2·5 trans fusions 
per PYO in the year before enrolment), falling to less than 
0·3 transfusions per PYO for observation periods beyond 
1 year, when transfusions were given only as a pre caution-
ary measure for surgery or trauma. The transfusion rate 
was higher in the preparatory period before gene therapy 
(42·9 trans fusions per PYO, equal to 3·6 transfusions per 
person-month of observation), mainly because of standard 
use as bleeding prophylaxis for invasive procedures such 
as bone marrow aspiration or harvest, central venous 
cathether positioning, and peripheral blood stem cell 
leuko apheresis. Two patients (patients 8 and 9) who 
received mobilised peripheral blood-derived drug product 
had a faster increase in platelet count after gene therapy 
compared with those who received bone marrow-derived 
drug product (appendix pp 9, 10). None of the treated 
patients required splen ectomy.
The improvement in platelet count was accompanied 
by a reduction in the rate and severity of bleeding events 
(figure 4C). No severe bleeding events were reported after 
gene therapy, and a pronounced reduction in moderate 
bleeding events was also seen after gene therapy. 
Bleeding events after gene therapy were predominantly 
related to the skin or mucosa and none resulted in 
hospitalisation (figure 4D).
Patient 4 had severe refractory autoimmune thrombo-
cytopenia23 before gene therapy and was treated both 
before and after gene therapy with immunosuppressive 
drugs (high-dose intravenous immunoglobulin, steroids, 
and rituximab) and with thrombopoietin receptor 
agonists for 8 months after gene therapy. This patient 
became independent of platelet transfusions after gene 
therapy, with only one transfusion in the 1–2 year 
Figure 4: Platelets and bleeding events
Gene therapy was administered on day 1 (month 0). (A) Percentage of platelets expressing WASP, as measured by flow cytometry. (B) Mean (SD) platelet count (× 109 
cells per L). SD is not plotted for follow-up at 60 months because data were available for only two patients. (C) Moderate or severe bleeding events (per PYO) for each 
observation period. Error bars represent the 95% CI. (D) Distribution of all bleeding events for each observation period, by body site. Total number of events for each 
observation period is shown in the centre of each chart. WASP=Wiskott-Aldrich syndrome protein. PYO=patient-year of observation. 
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observation period and one transfusion in the 4–5 year 
observation period; these transfusions were pre cautionary 
because of a surgical procedure and head trauma, 
respectively. Patient 2 developed severe auto immune 
thrombocytopenia approximately 3 months after gene 
therapy, which resolved within 6 months. Patient 9 had a 
prolonged history of inflammatory and autoimmune 
manifestations (Crohn-like enterocolitis, pyoderma 
gangrenosum, and arthritis) requiring multiple chronic 
treat ments before gene therapy.18 However, disease 
symptoms and signs fully resolved after gene therapy 
(appendix p 11). A panel of 15 serum autoantibodies were 
tested before and after gene therapy. The incidence 
of auto immune antibodies was highest at baseline 
(ten positive reports in four of eight patients) but declined 
by year 1 (two positive reports in two of eight patients) and 
fell further at year 3 (three positive reports in two of 
six patients; data not shown). Positive autoimmunity test 
results were inter mittent in most patients and were not 
associated with any clinical manifestations, except for 
autoimmune thrombo cytopenia in patient 2.
Four patients were living in a protected environment 
before entering the study but were able to enter the 
community after gene therapy. The clinical improvements 
enabled patients to attend school (according to age), have 
normal social interactions, and to take part in sporting 
activities.
Discussion
This interim analysis of data from a study of eight patients 
with severe Wiskott-Aldrich syndrome, six of whom have 
been followed up for more than 3 years, suggests that 
this disease can be successfully treated by one infusion of 
autologous CD34+ HSPCs transduced with a lentiviral 
vector encoding for a functional WAS gene, preceded by 
a reduced-intensity conditioning regimen. Treatment 
outcome was favourable for all eight patients, and all 
patients were alive and well at the last follow-up visit.
Preparatory conditioning was tolerated as anticipated 
in all eight patients. Expected chemotherapy-related 
severe neutropenia was transient, and all eight patients 
showed good haemopoietic recovery thereafter, with only 
one patient needing administration of granulocyte 
colony-stimulating factor. The infusion of autologous 
lentiviral vector-transduced HSPCs was well tolerated, 
with no adverse reactions. No immune response against 
the vector or WASP was detected. Sustained multilineage 
engraftment of genetically corrected cells was recorded 
in peripheral blood and bone marrow, attributable to 
persistent engraftment of HSPCs in the bone marrow 
over time. Of note, haemopoiesis is driven by distinct 
subsets of HSPCs, which contribute differently in early 
and late phases of reconstitution.24
Expression of vector-derived WASP in most lymphoid 
cells and platelets led to improvement of immune 
function and platelet counts. This expression resulted in 
clinical benefit for patients, who showed a progressive 
amelioration of their clinical status, with protection from 
severe infections and bleeding events.
It should be considered that this study has a small 
sample size and is based at one centre, is single arm, and 
is open label, using the patient’s prestudy status as the 
control for the assessment of efficacy of gene therapy. 
This study design is justified by the rarity and severity of 
the disease and type of intervention. The study design 
was agreed with the EMA and its PDCO and takes 
EU guidelines into consideration.
With respect to safety, adverse events and serious 
adverse events were recorded most frequently during the 
first 6 months after gene therapy. These events were 
mainly of infectious origin. Two serious adverse events 
that were related to infections—both within the first 
6 months after gene therapy—were life-threatening, but 
these events resolved with minor sequelae in one patient.16 
Infections are not unexpected during ongoing immune 
reconstitution because of the time needed for 
engraftment, similar to patients who undergo traditional 
allogeneic bone marrow transplantation.9,10 No graft 
failure was reported after gene therapy; graft-versus-host 
disease was not reported either, a finding that was 
expected because of the autologous nature of the 
procedure. No organ deterioration related to disease 
progression or compli cations or to treatment-related 
toxicity was seen. Importantly, malig nant diseases 
typically reported in patients with Wiskott-Aldrich 
syndrome have not been detected in any of the eight 
patients treated to date. Intervention-free survival (ie, free 
from second HSPC transplant, splenectomy, or chronic 
immunosuppression) is 100% as of the data cutoff.
Autoimmunity is a key risk factor for a poor outcome 
in patients with Wiskott-Aldrich syndrome.5,18 Despite 
the presence of circulating autoantibodies, clinical auto-
immune manifestations reported after gene therapy 
were restricted to one case of transient autoimmune 
thrombocytopenia occurring in the early follow-up phase 
and one case already present before treatment. No 
autoimmune endocrinopathies were seen after gene 
therapy. Importantly, the pre-existing severe refractory 
autoimmune thrombocytopenia in one patient and 
severe autoimmune and autoinflammatory clinical 
manifestations in another resolved completely after 
treatment. Eczema was cleared in seven of eight patients; 
in the one patient in whom eczema did not resolve, 
eczema was mild and intermittent by 3-year follow-up. 
These results indicate that the immune dysregulation 
that predisposes patients with Wiskott-Aldrich syndrome 
to develop autoimmune manifestations could be ameli-
orated by insertion of the correct WAS gene and 
establishment of functional T cells and B cells. These 
data accord with the finding that lentiviral gene therapy 
corrected the alterations of both central and peripheral 
B-cell tolerance checkpoints and ameliorated B-cell 
development and functionality in patients with Wiskott-
Aldrich syndrome.25,26 Of note, the engraftment and 
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expansion of gene-corrected B cells expressing WASP 
could have been favoured by pretreatment rituximab-
mediated depletion of B cells, particularly autoreactive 
B cells, highlighting the key role of this drug in the 
conditioning of patients with Wiskott-Aldrich syndrome 
before gene therapy.
Validated quality-of-life general assessments might 
not adequately assess the key disease-related effects 
of Wiskott-Aldrich syndrome and, hence, risk under-
estimating the impaired quality of life of a patient with 
this disease. In this study, we used a simple questionnaire 
(appendix pp 1, 2) to assess the effect of disease burden 
on patients’ quality of life before and after treatment, 
focusing in particular on life restrictions, social 
interactions, attendance to educational services and 
participation in sporting activities. Moreover, we also 
assessed the frequency of hospitalisation before and after 
gene therapy, as a measure of medical care requirement 
affecting patients’ daily life. Overall, gene therapy resulted 
in a substantial improve ment in quality of life for patients 
and their families, with patients socialising in their 
community with peers, attending school (according to 
age), starting to participate in sporting activities, and 
progressively reducing their time spent in hospital and 
their chronic medical care needs. Further work would be 
needed to develop quality-of-life assessments specific to 
Wiskott-Aldrich syndrome for implementation in a future 
clinical trial.
By comparison with a British and French gene therapy 
clinical study in patients with Wiskott-Aldrich syndrome 
that used a lentiviral vector structure,27 our results are 
similar with respect to improvement in immune 
functions and resolution of eczema and autoimmunity, 
but they differ with respect to the degree of HSPC 
engraftment, immune reconstitution, and platelet count 
increase. Specifically, three of four patients in the British 
and French trial who did not have splenectomy had 
platelet counts lower than 20 × 10⁹ cells per L after gene 
therapy (median follow-up after gene therapy, 2 years 
[range 9–30 months]), compared with our study in which 
none of the eight patients had splenectomy and all eight 
patients had platelet counts greater than 20 × 10⁹ cells 
per L after gene therapy at the last follow-up visit. 
Immune reconstitution was suboptimum in the British 
and French trial because only two of six patients with 
follow-up longer than 1 year stopped immunoglobulin 
replacement therapy and CD8+ T cells remained low in 
most patients. This finding contrasts with our results 
showing normalisation of lymphocyte counts in seven of 
eight patients, allowing the suspension of antimicrobial 
prophylaxis in all eight patients after gene therapy and 
dis continuation of intravenous immunoglobulin in all 
seven patients with follow-up longer than 1 year, followed 
by vaccine administration in five patients with a 
protective antibody response for most vaccines. Differ-
ences in disease severity, age at treatment, study conduct, 
and pre conditioning might have contributed to the 
diverse outcome between the two studies. Furthermore, 
the specific vector manufacture and transduction 
processes could account for the differences seen in 
the correction level in vitro and in vivo. Although the 
CD34+ cell dose was similar (median 9·6 × 10⁶ cells 
per kg in our study vs 7·3 × 10⁶ cells per kg in the British 
and French trial), median vector copy number per 
genome in transduced CD34+ cells was 2·4 in our study 
and 1·3 in the British and French trial.27 Moreover, the 
degree of in-vivo gene marking in the myeloid lineage in 
the British and French trial was lower compared with our 
trial (median vector copy number per genome 0·1 in the 
British and French trial vs 0·8 in our study at the last 
available follow-up visit). This difference was seen 
despite us using a less intense dose of chemotherapy in 
our study.
Insertional mutagenesis and consequent leukaemia is 
considered a known risk related to gene therapy using 
integrating viral vectors. In a German study of gene 
therapy for Wiskott-Aldrich syndrome using a γ-retroviral 
vector,11 seven of ten treated patients developed leuk-
aemia, which was attributed to the type of vector used in 
combination with a strong promoter. Leukaemias were 
diagnosed 1–5 years after gene therapy, with four of seven 
cases diagnosed within 3 years. In our study that used a 
lentiviral vector, no clonal expansion or leukaemia 
development have been recorded to date. The lack of a 
transcriptionally active long-terminal repeat of the 
self-inactivating lentiviral backbone, combined with a 
moderately active internal promoter to drive transgene 
expression, such as the WASP endogenous promoter, is 
a major safety advantage of the vector compared with the 
γ-retroviral vector used in the German Wiskott-Aldrich 
syndrome study.11 The insertion site analyses we did in 
our current trial show that the vector insertions are 
polyclonal, and there is no evidence of any aberrant 
selection of clones carrying insertion sites in the 
proximity of known oncogenes.
In the British and French clinical study,27 no leukaemia 
events were reported in patients followed up for 
7–42 months.To date, more than 100 patients with various 
inherited diseases have been treated using lentiviral 
vectors and no causally related adverse events have been 
reported.28
The current accepted curative treatment for Wiskott-
Aldrich syndrome is allogeneic HSPC transplantation 
when an HLA-identical donor is available. Historically, 
transplants from alternative donors were characterised 
by increased risk of toxicity and mortality, and larger 
cohorts using current alternative donor transplant 
protocols have not been published (eg, NCT02064933 by 
the Primary Immune Deficiency Treatment Consortium). 
Findings of two large retrospective series of patients who 
received HSPC transplants—an inter national study of 
194 patients by Moratto and colleagues9 and a single-
centre US study of 47 patients by Shin and colleagues10—
showed overall survival of 84% and 81%, respectively, 
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with most deaths occurring within the first 3–6 months 
after transplantation and severe infection being the main 
cause of death. In the international study,9 a risk factor 
for determining outcome was age at the time of 
transplant, with patients older than 5 years and an 
unrelated donor having a poorer outcome. In the US 
study,10 older children were most likely to die: seven of 
nine patients who died were older than 2 years at the 
time of HSPC transplantation. In patients with Wiskott-
Aldrich syndrome who underwent allogeneic HSPC 
transplantation, complications were most common 
within the first year after the transplant (46%), with the 
main complications being infections needing hospitali-
sation (55 [28%] of 194 patients in the international 
study),9 autoimmune manifestations (27 [14%] of 
194 patients in the international study,9 and 17 [55%] of 
31 patients receiving a transplant after 2001 in the 
US study),10 severe (grade >2) acute graft-versus-host 
disease (22 [11%] of 194 patients in the international 
study,9 and between 15% and 44% of patients in the 
US study),10 and graft failure or rejection (13 [7%] of 
194 patients in the international study,9 and three [6%] 
of 47 patients in the US study).10 Autoimmune cytopenias 
resolved in most patients in the international study, with 
median time to recovery of 14 months after HSPC 
transplantation.9 The most common cytopenia was 
thrombocytopenia, typically occurring within the first 
6 months after HSPC transplantation in the international 
study.9 A recent improvement in outcome of HSPC 
transplantation in patients with Wiskott-Aldrich 
syndrome29 has been obtained owing to advances in 
graft manipulation techniques and optimisation of 
conditioning regimens.30
With the limitations of a single-centre study, our results 
are suggestive of a more benign safety profile, with fewer 
complications after gene therapy compared with those 
previously reported after HSPC transplantation.9,10 No 
deaths were reported in our study, with a median age at 
treatment of 2·2 years (range 1·1–12·4). Gene therapy is, 
therefore, a potentially suitable alternative to HSPC 
transplantation because of the absence of graft-versus-
host disease, since gene therapy is an autologous 
procedure and is preceded by use of a reduced-intensity 
conditioning regimen. This strategy opens the possibility 
to treat adult patients with Wiskott-Aldrich syndrome 
with chronic complications, for whom allogeneic trans-
plantation would be associated with high risks; the report 
of successful lentiviral gene therapy in a 30-year-old 
patient with severe Wiskott-Aldrich syndrome mani-
festations supports this idea.31
Successful HSPC transplantation has been proven to 
correct thrombocytopenia in most patients. In the 
international study by Moratto and colleagues,9 HSPC 
transplantation resulted in a significant increase of mean 
platelet count at the last follow-up visit; however, in 
36 (24%) of 152 patients, the platelet count did not 
return to normal and, in 14 (9%) patients, severe 
thrombocytopenia was persistent (platelet count 
10–42 × 10⁹ cells per L). Analysis of variables in the study 
by Moratto and colleagues9 affecting the degree of 
thrombocytopenia correction after allogeneic HSPC 
transplantation showed a significant effect of myeloid 
chimerism on the reconstitution of platelet counts in 
patients with follow-up longer than 1 year. Although gene 
therapy in our study did not return platelet counts to 
normal, platelet levels increased significantly and platelets 
were of a typical size, reducing the risk of bleeding and 
related disorders, and no patients needed to be admitted 
to hospital because of bleeding events after treatment. It 
is noteworthy that the patients in our study had platelet 
counts after treatment in the range of those measured in 
patients with mixed donor–host chimerism after 
successful allogeneic bone marrow transplant (range 
30 000–150 000 cells per µL).9 This observation suggests 
that, in gene therapy, a minimum level of engraftment 
could be needed to correct thrombocytopenia with a 
significant effect on recon stitution of platelet number. We 
noted some correlation between median platelet counts 
and the proportion of transduced clonogenic progenitors 
in bone marrow at 1 year after gene therapy (appendix p 12). 
Because bone marrow contains a mixed population of 
transduced and non-transduced HSPCs and, hence, 
megakaryocytes both positive and negative for WASP, 
and since the percentage of WASP-positive platelets in 
peripheral blood was considerably higher than the 
percentage of lentiviral vector-transduced HSPCs in bone 
marrow (median 76·6% [figure 4A] vs 42·1% [figure 2A] at 
1 year of follow-up), it is possible that a selective advantage 
of platelets expressing WASP exists and favours their 
survival in the periphery or their release from bone 
marrow into peripheral blood.
Correction of thrombocytopenia is of paramount 
importance for cure of Wiskott-Aldrich syndrome, 
particularly for patients with milder disease in whom 
thrombocytopenia is the prominent feature. Therefore, 
efforts to improve correction of platelet counts should be 
made in the future. Further optimisation of the 
conditioning regimen could increase lentiviral vector-
corrected HSPC engraftment and lead to enhanced 
platelet recovery. Improvement of the vector construct 
might be also considered but should be weighted with 
the potential risks of using a stronger viral promoter.32
Differences in stem-cell source, cell dose, purification, 
manipulation, and conditioning might account for the 
longer duration of neutropenia noted in our study 
compared with allogeneic transplantation.29,30
CD34+ cells from bone marrow and mobilised 
peripheral blood have similar capacity to re-establish long-
term haemopoiesis after allogeneic HSPC transplantation, 
but the use of mobilised peripheral blood is associated 
with a reduction in time to engraftment, probably 
attributable to differences in composition of progenitor 
cells.33 Studies in a larger cohort of patients are needed to 
establish if ex-vivo gene-corrected CD34+ cells from 
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mobilised peripheral blood and bone marrow differ in 
their biological properties and capacity to restore 
haemopoiesis after gene therapy for Wiskott-Aldrich 
syndrome.
In conclusion, data from the interim analysis of our 
study suggest that patients with severe Wiskott-Aldrich 
syndrome can be treated with gene therapy to enable 
restoration of immune function, substantially increased 
platelet count, and reduction in autoimmunity; patients 
had strikingly reduced incidence of disease-specific 
clinical events without complications related to the drug 
product. Furthermore, these improve ments were 
sustained or increased over the duration of follow-up, 
leading to substantial improvements in quality of life for 
patients. Longer follow-up through a dedicated registry, 
along with results in a larger cohort of patients with 
Wiskott-Aldrich syndrome, will provide further evidence 
of the long-term safety and efficacy of this treatment.
Contributors
FF and MPC were key study investigators, provided clinical care of 
patients, and collected, reviewed, analysed, and interpreted data. 
AA designed and coordinated the study as principal investigator. StGa 
and MGV participated in study design and contributed to data analysis. 
StGi, IB, SaSc, and FD designed the molecular and immunological 
experimental plan, analysed biological patient samples, and contributed 
to data interpretation. MF, CF, and EA collected and managed data. CD 
and KvR contributed to protocol amendments and reviewed, verified, 
and interpreted data. GA oversaw the study and data analyses. 
EJC-S provided critical analysis and review of the publication. FB, MM, 
MEB, VC, AAA, RP, DC, RF, PS, and SaGa participated in patients’ 
assessment, treatment and follow up and provided data for the clinical 
trial. MHA referred and managed patients and provided data for the 
clinical trial. AB, FAS, LB-R, and SeSc did experimental analyses on 
patient samples and contributed to data analysis. HMW assessed specific 
antibody responses to vaccinations. LB did vector insertion analyses and 
contributed to data interpretation. MC coordinated patient’s assessments 
and managed biological samples. AV contributed to data review and data 
interpretation. MGR contributed to study design, data review, and data 
interpretation. FC contributed to study design, treatment of patients, 
data review, and data interpretation. LN had the idea for the study and 
contributed to study design and data interpretation.
Declaration of interests
LN is an inventor on pending and issued patents on lentiviral vector 
technology. At the time of the interim study reporting, KvR, EJC-S, and GA 
were employed by and held stock in GlaxoSmithKline. CD was a contractor 
at GlaxoSmithKline at the time of the interim study reporting and is now 
employed and holds stock in Orchard Therapeutics. MHA reports grants, 
consultancy fees, and stock ownership from GlaxoSmithKline, non-
financial support, travel support, and honoraria from Octapharma, 
honoraria from CSL Behring and MSD, and non-financial support from 
Medac and Shire, outside of the submitted work. LB reports personal fees 
from GlaxoSmithKline during the conduct of the study, for consulting 
activity on safety and integration site analysis for the trial object of the 
study. FF, MPC, StGa, StGi, FD, FB, MM, MEB, VC, AAA, MF, CF, EA, 
SaSc, IB, SeSc, LB-R, RP, MC, DC, FAS, AB, HMW, RF, PS, SaGa, AV, 
MGV, MGR, FC, and AA declare no competing interests.
Data sharing
For further information, please contact the corresponding author.
Acknowledgments
The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) is a 
joint venture between the Italian Telethon Foundation and Ospedale San 
Raffaele (OSR). The TIGET-WAS gene therapy clinical trial 
(NCT01515462) was originally sponsored by the Italian Telethon 
Foundation  and promoted by SR-Tiget. Wiskott-Aldrich syndrome gene 
therapy was subsequently in-licensed to GlaxoSmithKline in 2014, and 
GlaxoSmithKline became the financial sponsor of the trial. The Italian 
Telethon Foundation and OSR are entitled to receive milestone 
payments and royalties on commercialisation of such therapies. 
GlaxoSmithKline divested this gene therapy before submission of this 
report to Orchard Therapeutics (April, 2018). We thank all medical and 
nursing personnel of the Paediatric Immunohaematology and 
Haematology and Bone Marrow Transplant Unit of San Raffaele 
Hospital (Milan, Italy); Stefano Zancan and all personnel of the SR-Tiget 
Clinical Trial Office; local referring doctors who helped with patients’ 
management; and all eight patients who participated in this study and 
their families. We acknowledge the Italian Telethon Foundation  for 
continuous support and guidance. We thank Michela Gabaldo (SR-Tiget) 
for support to projects; and Giuliana Tomaselli, Luisella Meroni, and 
Samih El Hossary (SR-Tiget) for support to patients.
References
1 Thrasher AJ, Burns SO. WASP: a key immunological multitasker. 
Nat Rev Immunol 2010; 10: 182–92.
2 Ochs HD, Thrasher AJ. The Wiskott-Aldrich syndrome. 
J Allergy Clin Immunol 2006; 117: 725–38.
3 Bosticardo M, Marangoni F, Aiuti A, Villa A, Roncarolo MG. 
Recent advances in understanding the pathophysiology of 
Wiskott-Aldrich syndrome. Blood 2009; 113: 6288–95.
4 Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. 
A multi-institutional survey of the Wiskott-Aldrich syndrome. 
J Pediatr 1994; 125: 876–85.
5 Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in 
Wiskott-Aldrich syndrome: risk factors, clinical features, and 
outcome in a single-center cohort of 55 patients. Pediatrics 2003; 
111: e622–27.
6 Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type 
on outcome of bone marrow transplantation for Wiskott-Aldrich 
syndrome: collaborative study of the International Bone Marrow 
Transplant Registry and the National Marrow Donor Program. 
Blood 2001; 97: 1598–603.
7 Kobayashi R, Ariga T, Nonoyama S, et al. Outcome in patients with 
Wiskott-Aldrich syndrome following stem cell transplantation: 
an analysis of 57 patients in Japan. Br J Haematol 2006; 135: 362–66.
8 Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term 
outcome following hematopoietic stem-cell transplantation in 
Wiskott-Aldrich syndrome: collaborative study of the European 
Society for Immunodeficiencies and European Group for Blood and 
Marrow Transplantation. Blood 2008; 111: 439–45.
9 Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and 
lineage-specific chimerism in 194 patients with Wiskott-Aldrich 
syndrome treated by hematopoietic cell transplantation in the 
period 1980–2009: an international collaborative study. Blood 2011; 
118: 1675–84.
10 Shin CR, Kim M-O, Li D, et al. Outcomes following hematopoietic 
cell transplantation for Wiskott-Aldrich syndrome. 
Bone Marrow Transplant 2012; 47: 1428–35.
11 Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for 
Wiskott-Aldrich syndrome: long-term efficacy and genotoxicity. 
Sci Transl Med 2014; 6: 227ra33.
12 Dupré L, Trifari S, Follenzi A, et al. Lentiviral vector-mediated gene 
transfer in T cells from Wiskott-Aldrich syndrome patients leads to 
functional correction. Mol Ther 2004; 10: 903–15.
13 Modlich U, Navarro S, Zychlinski D, et al. Insertional 
transformation of hematopoietic cells by self-inactivating lentiviral 
and gammaretroviral vectors. Mol Ther 2009; 17: 1919–28.
14 Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical safety and 
efficacy of human CD34(+) cells transduced with lentiviral vector 
for the treatment of Wiskott-Aldrich syndrome. Mol Ther 2013; 
21: 175–84.
15 Marangoni F, Bosticardo M, Charrier S, et al. Evidence for 
long-term efficacy and safety of gene therapy for Wiskott-Aldrich 
syndrome in preclinical models. Mol Ther 2009; 17: 1073–82.
16 Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic 
stem cell gene therapy in patients with Wiskott-Aldrich syndrome. 
Science 2013; 341: 1233151.
17 Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T. Therapeutic drug 
monitoring is essential for intravenous busulfan therapy in 
pediatric hematopoietic stem cell recipients. Pediatr Transplant 2011; 
15: 580–88.
Articles
www.thelancet.com/haematology   Vol 6   May 2019 e253
18 Brigida I, Scaramuzza S, Lazarevic D, et al. A novel genomic 
inversion in Wiskott-Aldrich-associated autoinflammation. 
J Allergy Clin Immunol 2016; 138: 619–22.
19 Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic 
stem-cell gene therapy in early-onset metachromatic 
leukodystrophy: an ad-hoc analysis of a non-randomised, 
open-label, phase 1/2 trial. Lancet 2016; 388: 476–87.
20 Lidonnici MR, Paleari Y, Tiboni F, et al. Multiple integrated 
non-clinical studies predict the safety of lentivirus-mediated gene 
therapy for β-thalassemia. Mol Ther Methods Clin Dev 2018; 11: 9–28.
21 Comans-Bitter WM, de Groot R, van den Beemd R, et al. 
Immunophenotyping of blood lymphocytes in childhood: reference 
values for lymphocyte subpopulations. J Pediatr 1997; 130: 388–93.
22 Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets 
in healthy children from birth through 18 years of age: the Pediatric 
AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 
2003; 112: 973–80.
23 Mahlaoui N, Pellier I, Mignot C, et al. Characteristics and outcome 
of early-onset, severe forms of Wiskott-Aldrich syndrome. 
Blood 2013; 121: 1510–16.
24 Scala S, Basso-Ricci L, Dionisio F, et al. Dynamics of genetically 
engineered hematopoietic stem and progenitor cells after 
autologous transplantation in humans. Nat Med 2018; 24: 1683–90.
25 Castiello M, Scaramuzza S, Pala F, et al. B-cell reconstitution after 
lentiviral vector-mediated gene therapy in patients with 
Wiskott-Aldrich syndrome. J Allergy Clin Immunol 2015; 
136: 692–702.
26 Pala F, Morbach H, Castiello M, et al. Lentiviral-mediated gene 
therapy restores B cell tolerance in Wiskott-Aldrich syndrome 
patients. J Clin Invest 2015; 125: 3941–51.
27 Hacein-Bey Abina S, Gaspar H, Blondeau J, et al. Outcomes 
following gene therapy in patients with severe Wiskott-Aldrich 
syndrome. JAMA 2015; 313: 1550–63.
28 Cavazzana M, Ribeil J, Lagresle-Peyrou C, André-Schmutz I. 
Gene therapy with hematopoietic stem cells: the diseased bone 
marrow’s point of view. Stem Cells Dev 2017; 26: 71–76.
29 Elfeky R, Furtado-Silva J, Chiesa R, et al. One hundred percent 
survival after transplantation of 34 patients with Wiskott-Aldrich 
syndrome over 20 years. J Allergy Clin Immunol 2018; 142: 1654–56.
30 Balashov D, Laberko A, Shcherbina A, et al. A conditioning 
regimen with plerixafor is safe and improves the outcome of 
TCRαβ+ and CD19+ cell-depleted stem cell transplantation in 
patients with Wiskott-Aldrich syndrome. Biol Blood Marrow Transpl 
2018; 24: 1432–40.
31 Morris E, Fox T, Chakraverty R, et al. Gene therapy for 
Wiskott-Aldrich syndrome in a severely affected adult. Blood 2017; 
130: 1327–35.
32 Astrakhan A, Sather BD, Ryu BY, et al. Ubiquitous high-level gene 
expression in hematopoietic lineages provides effective lentiviral 
gene therapy of murine Wiskott-Aldrich syndrome. Blood 2012; 
119: 4395–407.
33 Teipel R, Oelschlägel U, Wetzko K, et al. Differences in cellular 
composition of peripheral blood stem cell grafts from healthy stem 
cell donors mobilized with either G-CSF alone or G-CSF and 
plerixafor. Biol Blood Marrow Transpl 2018; 24: 2171–77.
